What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

REGN Factor-Based Stock Analysis - Benjamin Graham June 25, 2025 — 02:07 pm EDT Written by John Reese for Validea -> ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. Regeneron missed analysts’ revenue expectations by 6.1% last ...

Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per share. This compares to earnings of $11.56 per share a year ago. These ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

Regeneron Pharmaceuticals: A Financial Overview Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages.

REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...